Pharmacy Times previews enlicitide, survodutide, diet and heart failure risk, and pharmacist-led HF care ahead of the AHA Scientific Sessions in Chicago.
|Articles|June 19, 2015
Striving for Excellence: The Honest Apothecary
Pharmacy Podcast Show host Todd Eury speak to Jason Poquette, RPh, creator of The Honest Apothecary.
Advertisement
Pharmacy Podcast Show host Todd Eury speaks to Jason Poquette, RPh, creator of The Honest Apothecary. This blog delves into the profession of pharmacy, pharmacy careers, pharmacy-related interviews, and other subjects pharmacists need to know about.
Advertisement
Related to this article
Expected in the first half of 2028, the planned separation would create a stand-alone retail pharmacy company with nearly 30,000 pharmacists.
RSV hospitalization raised short-term invasive pneumococcal disease risk, especially among unvaccinated individuals.
ADA guidance ties monitoring choices to therapy, risk, and preference. Brooke Hudspeth, PharmD, explains how pharmacists help individualize the plan.
The provider-administered IL-23 inhibitor improved ACR20 response vs placebo after 2 doses in the phase 3 INSPIRE-1 and INSPIRE-2 trials.
Two Kidney Week 2026 posters suggest remnant cholesterol–based markers may help stratify CKD severity and cardiovascular death risk on hemodialysis.
A pharmacy technician reflects on 3 patient encounters that reshaped his
understanding of what a real patient requires.
Treated patients also had fewer postacute hospitalizations and deaths, but individuals without risk factors saw no benefit.
Advertisement
Advertisement
Trending on Pharmacy Times
1
What Drives First-Line Immunotherapy Selection in NSCLC? Data, Payers, and Habit
2
Frontline Immunotherapy Options in NSCLC: Are Checkpoint Inhibitors Interchangeable?
3
AHA 2026: Insights on Oral PCSK9, Survodutide, and HF Care Come to Chicago
4
October Neurology News: Huntington Disease Gene Therapy, Remibrutinib in MS, and AI Medical Advice
5